2021 ESC/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the …

A Vahanian, F Beyersdorf, F Praz… - European heart …, 2022 - academic.oup.com
Health professionals are encouraged to take the ESC/EACTS Guidelines fully into account
when exercising their clinical judgment, as well as in the determination and the …

Tricuspid regurgitation: recent advances in understanding pathophysiology, severity grading and outcome

RT Hahn, LP Badano, PE Bartko… - European Heart …, 2022 - academic.oup.com
Heightened interest in tricuspid regurgitation (TR) stems from the consistent association of
mortality with greater severity of TR, and a low use of surgical solutions in the setting of high …

[HTML][HTML] Transcatheter treatment for tricuspid valve disease: Transcatheter treatment for tricuspid valve disease

F Praz, D Muraru, F Kreidel, P Lurz, RT Hahn… - …, 2021 - ncbi.nlm.nih.gov
Approximately 4% of subjects aged 75 years or more have clinically relevant tricuspid
regurgitation (TR). Primary TR results from anatomical abnormality of the tricuspid valve …

Transcatheter tricuspid valve interventions: landscape, challenges, and future directions

L Asmarats, R Puri, A Latib, JL Navia… - Journal of the American …, 2018 - jacc.org
Tricuspid regurgitation is a common finding in patients with left-sided valvular or myocardial
disease, often being a marker for late-stage chronic heart failure with a grim prognosis …

Predictors of procedural and clinical outcomes in patients with symptomatic tricuspid regurgitation undergoing transcatheter edge-to-edge repair

C Besler, M Orban, KP Rommel, D Braun… - JACC: Cardiovascular …, 2018 - jacc.org
Objectives: This study sought to investigate predictors of procedural success and clinical
outcomes in patients with tricuspid regurgitation (TR) at increased surgical risk undergoing …

2021 ESC/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the …

F Beyersdorf, A Vahanian, M Milojevic… - European journal of …, 2021 - academic.oup.com
731 F. Beyersdorf and A. Vahanian et al./European Journal of Cardio-Thoracic Surgery
guidelines, which is freely available via the ESC and EACTS website and hosted on the EHJ …

Prognostic implications of atrial vs. ventricular functional tricuspid regurgitation

X Galloo, MF Dietz, F Fortuni, EA Prihadi… - European Heart …, 2023 - academic.oup.com
Aims Atrial functional tricuspid regurgitation (AFTR) has shown distinctive
pathophysiological and anatomical differences compared with ventricular functional …

Tricuspid valve disease and cardiac implantable electronic devices

M Andreas, H Burri, F Praz, O Soliman… - European heart …, 2024 - academic.oup.com
The role of cardiac implantable electronic device (CIED)-related tricuspid regurgitation (TR)
is increasingly recognized as an independent clinical entity. Hence, interventional TR …

Value of echocardiographic right ventricular and pulmonary pressure assessment in predicting transcatheter tricuspid repair outcome

N Karam, M Mehr, M Taramasso, C Besler, T Ruf… - Cardiovascular …, 2020 - jacc.org
Objectives The aim of this study was to assess the value of echocardiographic right
ventricular (RV) and systolic pulmonary artery pressure (sPAP) assessment in predicting …

Tricuspid valve disease: diagnosis, prognosis and management of a rapidly evolving field

L Asmarats, M Taramasso… - Nature Reviews Cardiology, 2019 - nature.com
Tricuspid valve disease, and particularly tricuspid regurgitation, is a highly prevalent
condition with a complex pathophysiology and long-term adverse consequences. Although …